COVID-19 Vaccines Show Promise in Pregnant and Lactating Women

Strategic Insights -

Researchers at Beth Israel Deaconess Medical Center (BIDMC) have found that the Pfizer and Moderna COVID-19 vaccines trigger robust immune responses in pregnant and lactating women, offering a potential safeguard for infants against the virus. The study, published in the Journal of the American Medical Association, also revealed that maternal antibodies are transferred into infant cord blood and breast milk, providing further evidence for the effectiveness of vaccination in this population.

Key Takeaways:

  • The study found that both Pfizer and Moderna COVID-19 vaccines elicited similar levels of vaccine-induced antibody function and T cell responses in pregnant and non-pregnant women after the second vaccine dose.
  • Maternal vaccine antibodies were detected in infant cord blood and breast milk, suggesting that vaccinating pregnant mothers may protect infants from COVID-19 infection.
  • The researchers observed similar levels of cross-reactive immune responses against COVID-19 variants of concern B.1.1.7 and B.1.351 in pregnant and non-pregnant women.
  • The study included 103 women, aged 18-45, who received mRNA COVID-19 vaccines (54% received Pfizer and 46% received Moderna).
  • The science supports the use of COVID-19 vaccines in pregnant and lactating individuals, with potential benefits extending to newborns.
  • Future research should focus on determining the optimal timing of vaccination to maximize antibody transfer through the placenta and breast milk.

Statistics:

  • 103 women participated in the study, with 54% receiving Pfizer and 46% receiving Moderna COVID-19 vaccines.
  • The study found similar levels of vaccine-induced antibody function and T cell responses in all non-pregnant, pregnant, and lactating women after the second vaccine dose.
  • The vaccine-elicited antibody responses were greater than those seen after COVID-19 infections.
  • The study was supported by the National Institutes of Health (CA260476, AI146779), the Ragon Institute of MGH, MIT, and Harvard, the Massachusetts Consortium for Pathogen Readiness, and other organizations.

Sources:

  • Centers for Disease Control and Prevention (CDC)
  • Beth Israel Deaconess Medical Center (BIDMC)
  • Journal of the American Medical Association
  • Ragon Institute of MGH, MIT, and Harvard
  • National Institutes of Health (NIH)
  • Musicians Foundation
  • Reproductive Scientist Development Program from the Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Burroughs Wellcome Fund (HD000849)
  • Multidisciplinary AIDS Training Program (AI007387)
  • Harvard Clinical and Translational Science Center (TR002541)